Literature DB >> 8858533

Chemotherapy for meningiomas.

A P Kyritsis1.   

Abstract

The most efficacious treatment for meningiomas is surgery. For incompletely resected or recurrent tumors, radiotherapy can be given. However, when the meningioma is unresectable and/or all other previous treatments have failed, immunotherapy or chemotherapy may be considered for malignant tumors and immunotherapy and hormone therapy may be considered for benign ones. Various chemotherapy treatments that have shown some efficacy in individual cases include combinations of Adriamycin and Dacarbazine or Ifosfamide and Mesna. The most effective immunotherapy appears to be administration of interferon-alpha, which is relatively non-toxic and easily tolerated. However, more studies are needed to better define the roles of these agents in the management of a recurrent, unresectable, or malignant meningiomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858533     DOI: 10.1007/bf00165657

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

Authors:  S M Grunberg; M H Weiss; I M Spitz; J Ahmadi; A Sadun; C A Russell; L Lucci; L L Stevenson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

2.  Malignant transformation of recurrent meningioma with pulmonary metastases.

Authors:  D R LeMay; M N Bucci; S M Farhat
Journal:  Surg Neurol       Date:  1989-05

3.  Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy.

Authors:  U M Schrell; E F Adams; R Fahlbusch; R Greb; G Jirikowski; R Prior; F J Ramalho-Ortigao
Journal:  J Neurosurg       Date:  1990-11       Impact factor: 5.115

4.  Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas.

Authors:  E F Adams; U M Schrell; R Fahlbusch; P Thierauf
Journal:  J Neurosurg       Date:  1990-11       Impact factor: 5.115

5.  Mifepristone (RU 486) treatment of meningiomas.

Authors:  S W Lamberts; H L Tanghe; C J Avezaat; R Braakman; R Wijngaarde; J W Koper; H de Jong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

6.  Oestrogen and progesterone sensitivity in cultured meningioma cells.

Authors:  F Maiuri; S Montagnani; B Gallicchio; M Carandente; G G Lanza; F D'Andrea
Journal:  Neurol Res       Date:  1989-03       Impact factor: 2.448

7.  Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases.

Authors:  H Magdelenat; B F Pertuiset; M Poisson; P M Martin; J Philippon; B Pertuiset; A Buge
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

8.  Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay.

Authors:  S M Grunberg; A M Daniels; H Muensch; J R Daniels; L Bernstein; V Kortes; M H Weiss
Journal:  J Neurosurg       Date:  1987-03       Impact factor: 5.115

9.  Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.

Authors:  J W Koper; E C Zwarthoff; A Hagemeijer; R Braakman; C J Avezaat; M Bergström; S W Lamberts
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.

Authors:  D J Stewart; S Dahrouge; M Wee; S Aitken; H Hugenholtz
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more
  18 in total

1.  Salvage chemotherapy with CPT-11 for recurrent meningioma.

Authors:  Marc C Chamberlain; Denice D Tsao-Wei; Susan Groshen
Journal:  J Neurooncol       Date:  2006-04-21       Impact factor: 4.130

2.  Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Authors:  Richard G Everson; Yuuri Hashimoto; Jacob L Freeman; Tiffany R Hodges; Jason Huse; Shouhao Zhou; Joanne Xiu; David Spetzler; Nader Sanai; Lyndon Kim; Santosh Kesari; Andrew Brenner; Franco De Monte; Amy Heimberger; Shaan M Raza
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

3.  MR imaging- and MR spectroscopy-revealed changes in meningiomas for which embolization was performed without subsequent surgery.

Authors:  M Bendszus; I Martin-Schrader; M Warmuth-Metz; E Hofmann; L Solymosi
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

4.  Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo.

Authors:  Reshu Gupta; Venkateswara Rao Gogineni; Arun Kumar Nalla; Chandramu Chetty; Jeffrey D Klopfenstein; Andrew J Tsung; Sanjeeva Mohanam; Jasti S Rao
Journal:  Int J Oncol       Date:  2011-02-02       Impact factor: 5.650

5.  Meningiomas.

Authors:  Jeffrey Raizer
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

6.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

7.  Re-evaluation of cytostatic therapies for meningiomas in vitro.

Authors:  Annette Wilisch-Neumann; Doreen Pachow; Maren Wallesch; Astrid Petermann; Frank D Böhmer; Elmar Kirches; Christian Mawrin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

8.  Meningiomas.

Authors:  Sean Grimm; Jeffrey J Raizer
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

Review 9.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

Review 10.  Treatment of meningioma: an update.

Authors:  Anthony L D'Ambrosio; Jeffrey N Bruce
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.